285 related articles for article (PubMed ID: 32450591)
21. Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer: Past, Present, and Future.
McCall N; Higgins K
Oncology (Williston Park); 2021 Jun; 35(6):313-319. PubMed ID: 34139791
[TBL] [Abstract][Full Text] [Related]
22. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
23. [Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].
Leduc C; Antoni D; Quoix É; Noël G
Cancer Radiother; 2015 May; 19(3):192-7. PubMed ID: 25841992
[TBL] [Abstract][Full Text] [Related]
24. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY; Verma V
J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
26. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract][Full Text] [Related]
27. The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?
Ratnakumaran R; McDonald F
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):753-760. PubMed ID: 36117126
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
29. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
Levy A; Roux C; Mercier O; Issard J; Botticella A; Barlesi F; Le Péchoux C
Cancer Radiother; 2021 Oct; 25(6-7):517-522. PubMed ID: 34175225
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
[TBL] [Abstract][Full Text] [Related]
34. Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
Jasper K; Stiles B; McDonald F; Palma DA
J Clin Oncol; 2022 Feb; 40(6):635-641. PubMed ID: 34985915
[TBL] [Abstract][Full Text] [Related]
35. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
[TBL] [Abstract][Full Text] [Related]
36. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
37. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N; Gettinger S
Cancer J; 2020; 26(2):144-148. PubMed ID: 32205539
[TBL] [Abstract][Full Text] [Related]
38. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy for oligometastatic non-small cell lung cancer.
Salama JK; Schild SE
Cancer Metastasis Rev; 2015 Jun; 34(2):183-93. PubMed ID: 25948377
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
Ning MS; Gomez DR; Heymach JV; Swisher SG
Transl Lung Cancer Res; 2019 Feb; 8(1):97-106. PubMed ID: 30788239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
